Clinical Trial Update: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II study of Zaltrap (aflibercept) with chemotherapy for advanced resectable colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Rectal Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Status: WITHDRAWN